Related Experiment Video

Updated: Mar 23, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K

CDK4/6 Inhibition Overcomes Drug Resistance in HER2+ Breast Cancer

    Cancer Discovery
    |March 26, 2016
    PubMed

    Insights

    Resistance to targeted therapies in HER2(+) breast cancer is driven by cyclin D1 and CDK4. Targeting these specific proteins may overcome treatment resistance in HER2-positive breast cancer patients.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Cancer Research

    Background:

    • HER2-positive breast cancer is a subtype often treated with targeted therapies.
    • Resistance to these therapies remains a significant clinical challenge.
    • Understanding the molecular mechanisms of resistance is crucial for improving patient outcomes.

    Discussion:

    • Cyclin D1 and CDK4 are identified as key mediators of resistance to targeted treatments in HER2(+) breast cancer.
    • This finding suggests a potential therapeutic vulnerability in resistant tumors.
    • The interplay between HER2 signaling and cell cycle regulators like cyclin D1/CDK4 warrants further investigation.

    Key Insights:

    • Cyclin D1 and CDK4 play a critical role in the development of resistance to HER2-targeted therapies.
    • Inhibition of cyclin D1 and CDK4 could be a viable strategy to overcome treatment resistance.
    • This research sheds light on the molecular pathways driving therapeutic failure.

    Outlook:

    • Future research should focus on developing and testing drugs that target cyclin D1 and CDK4 in combination with HER2-targeted agents.
    • Clinical trials are needed to evaluate the efficacy of targeting cyclin D1/CDK4 in patients with resistant HER2(+) breast cancer.
    • This work opens new avenues for personalized medicine approaches in breast cancer treatment.

    More Related Videos

    Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

    Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

    Published on: April 26, 2024

    4.1K
    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

    Published on: August 11, 2017

    9.3K

    Related Concept Videos

    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    6.2K
    Inhibition of CDK Activity02:34

    Inhibition of CDK Activity

    5.6K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.9K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.1K
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    6.3K
    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    8.4K